관리-도구

편집 파일: 1628583940.M802863P4822.server.saraya-global.com,S=41103,W=41679:2,

Envelope-to: info@worldwide.saraya.com
Delivery-date: Tue, 10 Aug 2021 16:25:40 +0800
Date: Mon, 9 Aug 2021 19:51:03 +0000
To: info@worldwide.saraya.com
From: PMC Transactions AG <news@licensing4pharma.com>
Reply-To: PMC Transactions AG <info@licensing4pharma.com>
Message-ID: <KnxZ89N2rvt32QaAmGh8cWiIaaAP92enbQR5S4oiI@www.pmc-transactions.com>
MIME-Version: 1.0
Content-Type: multipart/alternative;
 boundary="b1_KnxZ89N2rvt32QaAmGh8cWiIaaAP92enbQR5S4oiI"
Content-Transfer-Encoding: 8bit
Subject: ***SPAM*** Divestments / Pharma & Healthcare

This is a multi-part message in MIME format.

--b1_KnxZ89N2rvt32QaAmGh8cWiIaaAP92enbQR5S4oiI
Content-Type: text/plain; charset=iso-8859-1
Content-Transfer-Encoding: quoted-printable

Dear Madam, Dear SirWe would like to inform you that we can offer the follo=
wing business opportunities for purchase or partnering:I. Business Opportun=
ities - Company Sales#1Project Name: FrankfurtHeadline:Pharmaceutical Drugm=
aker in Urology is seeking a Partner in North AmericaBusiness Description:T=
he company is one of the major medium-sized pharmaceutical companies in Eur=
ope, operating in more than 90 countries worldwide. It is an established ma=
nufacturer and marketer of prescription and pharmacy drugs. The owner is cu=
rrently exploring strategic options such as divesting a stake or cross-shar=
eholding with potential strategic partners in Urology capable of greatly ex=
panding the existing business particularly in North America.Transaction Typ=
e:Company SaleIndustry Sector:Pharma / Healthcare,OTC Drugs,Rx DrugsTherape=
utic Class:Ageing,Analgesia / Anaesthesia,Central Nervous System,Dermatolog=
y,Gastroenterology,Gynecology and Obstetrics,Phytotherapeutics,Respiratory =
System,Urology / Renal / Urogenital,Vitamins, Minerals, Nutraceuticals,Woun=
d HealingContinents:EuropeRegions:Counties:Revenue-Range:50-100 m EURreques=
t confidential information#2Project Name: CologneHeadline:Marketing Company=
 in Skin CareBusiness Description:The company for sale is a well-establishe=
d company specializing in the marketing and distribution of specific dermat=
ological products and cosmetics through a large sales force team to doctors=
, hospitals and pharmacies.Transaction Type:Company SaleIndustry Sector:Pha=
rma / Healthcare,OTC Drugs,Rx DrugsTherapeutic Class:DermatologyContinents:=
EuropeRegions:Western EuropeCounties:Austria,Germany,Liechtenstein,Switzerl=
andRevenue-Range:10-50 m EUREBITDA-Margin:16.7 %request confidential inform=
ation#3Project Name: HarvestHeadline:Pharmaceutical Marketing Company / Nat=
ural OTC-BrandsBusiness Description:A marketing and distribution enterprise=
 in Germany is put up for sale, which specialized in the marketing and sell=
ing of OTC-Brands (i.e. natural products, food supplements, medicinal produ=
cts and cosmetics). The profitable company is a fast growing company with a=
ttractive products and revenues in the mid 2-digit million EUR range.Transa=
ction Type:Company SaleIndustry Sector:Pharma / Healthcare,OTC DrugsTherape=
utic Class:Cardiovascular System,Dermatology,Gastroenterology,Immunology / =
Inflammation,Musculoskeletal System,Urology / Renal / UrogenitalContinents:=
EuropeRegions:Western EuropeCounties:GermanyRevenue-Range:10-50 m EUREBITDA=
-Margin:19.6 %request confidential informationII. Business Opportunities - =
Asset Sales#4Project Name: BrusselsHeadline:Bundle of Injectable Brands to =
treat Infections for saleBusiness Description:A bundle of injectable brande=
d Rx-medicines to treat severe infections and critical care settings is put=
 up for sale in Europe, Asia and Africa. The products are well-established =
with historic track record and extensive global use.Transaction Type:Asset =
SaleIndustry Sector:Pharma / Healthcare,Generics,Rx DrugsTherapeutic Class:=
Infections and InfestationsContinents:Africa,Asia,EuropeRegions:Counties:Re=
venue-Range:50-100 m EURDevelopment Stage:Marketedrequest confidential info=
rmation#5Project Name: ManhattanHeadline:Branded Niche Product to treat Inf=
ections/InfestationsBusiness Description:A branded drug for the treatment o=
f immunocompromised patients against parasite infestation is offered for sa=
le in the United States. The product is a well-established brand generating=
 sales of approximately USD 15-20 million. Due to a strategic realignment o=
f the seller, the brand is now being divested. If you are interested in ana=
lyzing a possible acquisition of the brand, please contact us.Transaction T=
ype:Asset SaleIndustry Sector:Pharma / Healthcare,Generics,Rx DrugsTherapeu=
tic Class:Infections and InfestationsContinents:North AmericaRegions:Counti=
es:United-StatesRevenue-Range:10-50 m USDDevelopment Stage:Marketedrequest =
confidential information#6Project Name: ParisHeadline:Brand to treat Pulmon=
ary DiseasesBusiness Description:A branded drug currently is put up for sal=
e, which is used therapeutically for the treatment of specific pulmonary di=
seases. The rights to the product can be acquired for Europe and other terr=
itories.Transaction Type:Asset SaleIndustry Sector:Pharma / Healthcare,Rx D=
rugsTherapeutic Class:Infections and Infestations,Respiratory SystemContine=
nts:Global / WorldwideRegions:Counties:Revenue-Range:100-250 m EURDevelopme=
nt Stage:Marketedrequest confidential informationIII. Business Opportunitie=
s - Licensing#7Project Name: BlueHeadline:Rx-Drug to treat Pain in Wound an=
d Skin Treatment ProceduresBusiness Description:Licensing partners sought i=
n Canada, Europe and LATAM for a registered, fast-acting, prescription-only=
 topical drug to provide analgesia prior to painful dermatological procedur=
esTransaction Type:Licensing OpportunityIndustry Sector:Pharma / Healthcare=
,Rx DrugsTherapeutic Class:Analgesia / Anaesthesia,Dermatology,Wound Healin=
gContinents:Europe,North America,Middle America,South AmericaRegions:Easter=
n Europe,Northern Europe,Southern Europe,Western EuropeCounties:Albania,Arm=
enia,Belarus,Bosnia-and-Herzegovina,Bulgaria,Croatia,Czech-Republic,Hungary=
,Macedonia,Moldova,Montenegro,Poland,Romania,Serbia,Slovakia,Slovenia,Ukrai=
ne,Denmark,Estonia,Finland,Iceland,Ireland,Kosovo,Latvia,Lithuania,Norway,S=
weden,United-Kingdom,Cyprus,Greece,Malta,Austria,Belgium,Germany,Luxembourg=
,Monaco,Netherlands,Switzerland,Canada,Belize,Costa-Rica,El-Salvador,Guatem=
ala,Honduras,Mexico,Nicaragua,Panama,Brazil,Chile,Paraguay,Uruguay,Venezuel=
aRevenue-Range:no salesDevelopment Stage:Preregistration,Registeredrequest =
confidential information#8Project Name: Budapest IIIHeadline:OTC Drug for t=
he treatment of venous Insufficiency and HaemorrhoidsBusiness Description:L=
icenses to a pharmacy-exclusive drug for the treatment of chronic venous In=
sufficiency and Haemorrhoids are available worldwide. In Europe a MRP proce=
ss iis running. Registration is expected to be finalized by the end of 2021=
. It is still possible to join the MRP till 1st Sept 2021, or to do a repea=
t use later from beninning of 2022. National process is also an option. As =
the product has a Zone  IV/B stability, the product can be registered and m=
arketed worldwide,Transaction Type:Licensing OpportunityIndustry Sector:Pha=
rma / Healthcare,OTC DrugsTherapeutic Class:Dermatology,GastroenterologyCon=
tinents:Africa,Asia,Australia / South-Pacific,Europe,North America,Middle A=
merica,South AmericaRegions:Counties:Revenue-Range:no salesDevelopment Stag=
e:Preregistration,Registeredrequest confidential information#9Project Name:=
 CopenhagenHeadline:Licenses available for Drug to treat Genital WartsBusin=
ess Description:Local licenses can be acquired worldwide for a drug used  f=
or the treatment of condyloma acuminata. Condylomata acuminata, also known =
as genital warts or condylomas for short, is a viral disease caused by the =
human papilloma virus (HPV). Transaction Type:Licensing OpportunityIndustry=
 Sector:Pharma / Healthcare,Rx DrugsTherapeutic Class:Gynecology and Obstet=
rics,Infections and Infestations,Urology / Renal / UrogenitalContinents:Afr=
ica,Asia,Australia / South-Pacific,Europe,Middle America,South America,Glob=
al / WorldwideRegions:Counties:AustraliaRevenue-Range:no salesDevelopment S=
tage:Preregistration,Registeredrequest confidential information#10Project N=
ame: PragueHeadline:Nystatin Combi-PackBusiness Description:Nystatin curren=
tly experiences a renaissance in the treatment of vaginal mycosis since man=
y fungi became resistent against azol-derivatives and Nystatin shows no res=
istence against those. A licensor is currently looking for partners for a u=
nique combination pack of a nystatin cream and a nystatin vaginal tablet fo=
r the commercialization of the combi-pack in various countries in Europe.

Marketing Authorizations are availble in Belgium, Denmark, Finland, Luxembo=
urg, Norway and Sweden.

In other countries the dossiers can be used for a repeat-use DCP.Transactio=
n Type:Licensing OpportunityIndustry Sector:Pharma / Healthcare,OTC Drugs,R=
x DrugsTherapeutic Class:Gynecology and ObstetricsContinents:EuropeRegions:=
Northern Europe,Western EuropeCounties:Denmark,Finland,Norway,Sweden,Belgiu=
m,LuxembourgRevenue-Range:no salesDevelopment Stage:Registeredrequest confi=
dential informationYou can find more business opportunities in our database=
 on our website.If, on the other hand, you are looking to divest companies,=
 divisions or non-core assets, we will be happy to support you. We organize=
 and execute all or parts of the sales process for you until the successful=
 completion of the transaction.We look forward to hearing from you.Many tha=
nk=B4s and best regards from Zug in SwitzerlandMarc RaberDr. M. RaberChairm=
an & CEOPMC Transactions AGAlisbachweg 22 C=A0/ CH-6315 OberaegeriSwitzerla=
ndPhone: +41 (0) 41 720 20 22Fax:+41 (0) 41 720 20 23Mobile:+41 (0) 79 358 =
21 86Web:www.pmc-transactions.comEmail:info@pmc-transactions.comUnsubscribe
--b1_KnxZ89N2rvt32QaAmGh8cWiIaaAP92enbQR5S4oiI
Content-Type: text/html; charset=us-ascii
Content-Transfer-Encoding: quoted-printable

Marketing Authorizations are availble in Belgium, Denmark, Finland, Luxembo=
urg, Norway and Sweden.

In other countries the dossiers can be used for a repeat-use DCP.</t=
d></tr><tr><td width=3D'15%'>Transaction Type=
:</td><td>Licensing Opportunity</sp=
an></tr><tr><td width=3D'15%'>Industry Sector=
:</td><td>Pharma / Healthcare,OTC D=
rugs,Rx Drugs</tr><tr><td width=3D'15%'>Therapeutic Class:</td><td>Gyneco=
logy and Obstetrics</td></tr><tr><td width=3D'15%'>Continents:</td><td>Eu=
rope</td></tr><tr><td width=3D'15%'>Re=
gions:</td><td>Northern Europe,West=
ern Europe</td></tr><tr><td width=3D'15%'>Counties:</td><td>Denmark,Finla=
nd,Norway,Sweden,Belgium,Luxembourg</td></tr><tr><td width=3D'15%'><=
span style=3D'color:#999999'>Revenue-Range:</td><td>no sales</td></tr><tr><td width=3D'15%'>Development Stage:</td><td>Registered</td></tr></table><a href=3D'https://www.pmc-t=
ransactions.com/transactions/details_licensing_opportunity.php?id=3DdE1HMjd=
FUThYd0NTbDJ5WUFkZTdZdz09'>request confidential information</a> <hr> <div styl=
e=3D'font-family:Arial'>You can find more business opportunities in our =
database on our website.If, on the other hand, you are looking to di=
vest companies, divisions or non-core assets, we will be happy to support y=
ou. We organize and execute all or parts of the sales process for you until=
 the successful completion of the transaction.We look forward to hea=
ring from you.Many thank&acute;s and best regards from Zug in Switze=
rlandMarc Raber Dr. M. Raber Chairman & CEO</div><t=
able style=3D'font-familay:Arial;font-size:0.9em;' border=3D'0' cellspacing=
=3D0 cellpadding=3D0><tr><td colspan=3D2>PMC =
Transactions AG</td></tr><tr><td colspan=3D2>Alisbachweg 22 C&nb=
sp;/ CH-6315 Oberaegeri Switzerland</td></tr><tr><td>Phone:</td><td> +41=
 (0) 41 720 20 22</td></tr><tr><td>Fax:</td><td>+41 (0) 41 720 20 23</td></=
tr><tr><td>Mobile:</td><td>+41 (0) 79 358 21 86</td></tr><tr><td>Web:</td><=
td><a href=3D"https://www.pmc-transactions.com">www.pmc-transactions.com</a></td></tr><tr><td>Email:=
</td><td><a href=3D"mailto:info@pmc-transactions.com">info@pmc-transactions.com</td></tr></table>=
<a href=3D'https://pmc-transactions.com/unsubscribe.php?url=3DYmM5NzE=3D'>U=
nsubscribe</a></body></html>

--b1_KnxZ89N2rvt32QaAmGh8cWiIaaAP92enbQR5S4oiI--